Danaher Corporation (NYSE:DHR) has built its reputation on acquiring businesses with durable market positions and improving their performance through its Danaher Business System, a framework for operational efficiency and continuous improvement. That model has helped turn the company into a major player in diagnostics, biotechnology, and life-sciences tools. But with its underlying growth still relatively modest, investors must decide whether the next phase of recovery justifies the price of its shares.
Danaher closed at $218.49 on October 7, 2026, compared with $208.77 a year earlier, a gain of approximately 4.7%. That is a relatively modest increase for a company whose investment case depends on a return to stronger growth. But before we dive into Danaher’s investment case, there are nine healthcare stocks other than DHR in our ranking of the 10 best healthcare stocks to buy according to hedge funds. Check out the complete list here.
The Recovery Is Real, but Not Yet Broad Enough
Danaher’s second-quarter 2026 results offered evidence that business conditions are improving. Revenue increased 5.5% year over year to $6.3 billion, while adjusted earnings per share rose 8% to $1.94. Non-GAAP core revenue rose 3.0% year-over-year, while non-GAAP core revenue, excluding respiratory testing revenue, grew 4.5% year-over-year. Read more about what you should know as an investor about Danaher’s bull and bear case here.
Danaher’s core growth is improving, but the 3% headline figure suggests that the underlying business has not yet returned to a particularly strong growth trajectory. However, there are encouraging signs beneath that number. Management reported that its life-sciences businesses delivered their strongest quarter in several years and that bioprocessing orders grew at a mid-teens rate.
Management expects full-year 2026 core revenue growth of 3%–4% and raised its full-year adjusted diluted net earnings per common share guidance to the $8.45 to $8.60 range, compared to a previous guidance of $8.35 to $8.55. The investment case therefore rests partly on whether improving customer activity becomes sustained revenue growth rather than a temporary improvement in orders and project timing. We meticulously crafted a list of the 7 Best Pharma Stocks to Invest In Now. Access the complete list here.
Masimo Adds Opportunity, Along With Execution Risk
Danaher’s acquisition of Masimo, completed in June for a cash purchase price of approximately $9.8 billion, adds another dimension to the valuation. Masimo develops patient-monitoring technologies, including pulse oximetry, and generated approximately $1.5 billion in revenue in 2025. Danaher expects the acquisition to provide additional earnings and sales opportunities through the expansion of product line diversity, which includes product offerings that support acute care settings.
The strategic rationale is understandable, as Masimo gives Danaher greater exposure to acute-care monitoring, complementing its existing diagnostics portfolio. Yet strategic fit is not the same as financial success. Investors need evidence that the acquired business can contribute enough growth and cash flow to justify the capital committed.
This is where Danaher’s operating model becomes important. If management can improve Masimo’s performance and expand its commercial reach, the acquisition could strengthen future earnings. If integration costs, financing expenses, or weaker-than-expected growth absorb those benefits, the deal could take longer to create value. For more insight into how Danaher compares with investment stories for other popular healthcare stocks, take a look at our insightful article on Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?.
The Valuation Leaves a Question Mark
At $218.49 per share, Danaher trades at approximately 25.6 times the midpoint of its 2026 adjusted EPS guidance of $8.45–$8.60, according to Seeking Alpha.
That multiple is not necessarily unreasonable for a business with strong market positions, substantial cash generation, and the potential to accelerate growth. Danaher generated $1.5 billion in operating cash flow and $1.3 billion in non-GAAP free cash flow during the second quarter, which demonstrates that the company can generate significant cash even while its core growth remains moderate.
The challenge is that investors are paying a premium before the anticipated recovery has fully materialized. If core growth accelerates as management expects, earnings could gradually support the valuation, but if demand remains uneven, the stock could struggle to deliver attractive returns even if Danaher continues to operate profitably.
Danaher’s investment thesis is ultimately about execution. Its portfolio, cash generation, and acquisition capabilities provide a foundation for long-term growth, but the current valuation requires more than a gradual improvement in business conditions. Investors need to see a broader, sustained recovery, as well as evidence that acquisitions such as Masimo can add to earnings without diluting the returns generated by the existing business.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center